We detected that high FZD6 expression was associated with poor cytogenetic risk classification, adverse ELN risk stratification, TP53 mutation, and short survival of AML patients, according to several powerful publicly available datasets. The gene discussed is TP53; the disease is acute myeloid leukemia.